



CSL Limited
ABN: 99 051 588 348
655 Elizabeth Street
Melbourne
Victoria 3000 Australia
T +613 9389 1911
F +613 9389 1434
[CSL.com](https://www.csl.com)

ASX Announcement

For immediate release

23 April 2024

Shareholder Information Meetings

Please find attached CSL Limited's presentation given at the Shareholder Information Meetings in Perth and Adelaide on 23 and 24 April 2024.

A recording of the presentation will be available in the 'Investors' section of the Company website at www.csl.com under Presentations.

Authorised by:

Fiona Mead
Company Secretary

For further information, please contact:

Investors:

Bernard Ronchi
Director, Investor Relations
CSL Limited
P: +61 3 9389 3470
E: bernard.ronchi@csl.com.au

The CSL logo is a red square with the letters 'CSL' in white, bold, sans-serif font. The background of the slide is a photograph of a laboratory with scientists in white coats and safety glasses working at a bench. One scientist in the foreground is using a pipette.

CSL

CSL Limited

Shareholder Briefing

April 2024

Joy Linton
CFO

Legal Notice

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, **CSL**) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (**ASX**), available at www.asx.com.au. This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project," "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL's ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a TM or [®] throughout this presentation are trademarks either owned by and/or licensed to CSL.

Joy Linton
CFO



Leading Positions in Large, Growing Markets

Global #1

in plasma protein therapies
~\$38 billion industry

Global #2

in influenza vaccines
~\$7 billion industry

Global #1

in iron
~\$5 billion industry



serving patients
and people in
100+
countries



\$13.31B
in annual
revenue



32,000
employees
worldwide



\$5.1B
CSL R&D Investment
over the last 5 years



340+
Plasma collection
centers



\$5.7B
capital expenditures
in the last 5 years

Our Businesses

CSL

```
graph TD; CSL[CSL] --- CSL_Behring[CSL Behring]; CSL --- CSL_Seqirus[CSL Seqirus]; CSL --- CSL_Vifor[CSL Vifor];
```

CSL Behring

Biotherapies &
Rare Disease

CSL Seqirus

Vaccines

CSL Vifor

Iron Deficiency &
Nephrology

Driven by Our Promise

Global Manufacturing Presence

CSL Behring



Bern, Switzerland



Broadmeadows, Australia



Marburg, Germany



Kankakee, United States



Wuhan, China

Global Manufacturing Presence

CSL Seqirus



Parkville, Australia



Holly Springs, United States



Liverpool, United Kingdom

CSL Vifor




St Gallen, Switzerland


Strong and Consistent Growth

Revenue


US\$



Net Profit



Dividends



1H24 Strong performance¹

Revenue +11%, NPATA^{2,3} +13%, NPAT +20%

CSL Behring

Strong growth across the portfolio especially Ig

- Ig +23%, KCENTRA[®] +12%, HAEGARDA[®] +9%
- Gross margin recovery underway
- Good progress with plasma initiatives
- Garadacimab filed

CSL Seqirus

Solid performance in a challenging season


- FLUAD[®] +14%
- Approval for world first sa-mRNA COVID vaccine
- aQIVc phase 3 - last patient enrolled

CSL Vifor


Well prepared for transitioning Iron market

- Successful TAVNEOS[®] EU launch
- Strong conversion to MIRCERA[®]

Revenue by Segment



CSL Share Price v 10 Year US Govt Bond Rate



Long Term, Sustainable Growth



1

Consistent strategy & disciplined execution



2

Targeted R&D with continuous innovation



3

Commitment to sustainability

Long Term, Sustainable Growth



1

Consistent strategy & disciplined execution



2

Targeted R&D with continuous innovation



3

Commitment to sustainability

Our 2030 Strategy


Focusing
in therapeutic
areas where
we excel

Innovating
across our
organization

Delivering
reliable supplies of
our products as
efficiently as possible

Growing
our pipeline with
sustainable, trusted
R&D platforms

Transforming
our digital
intellect and
technologies



Disciplined Management of Capital



Growing Cash Earnings

Maintain
strong balance
sheet

Returns to
shareholders

Re-invest in
the Business

Capital
structure

Partnering
approach

Long Term, Sustainable Growth



1

Consistent strategy & disciplined execution



2


Targeted R&D with continuous innovation



3

Commitment to sustainability

Our Therapeutic Areas and Platforms



CSL R&D Portfolio – FY24

As at Capital Markets Day
16 Oct 2023



Phase I



Phase II



Phase III



Registration/Post-Registration



R&D Focus

Investments Coming to Fruition




Deliver a Promising Portfolio

- CSL112
- Garadacimab HAE
- Clazakizumab ca-AbMR
- KCENTRA® Trauma
- CSL964 aGvHD
- Sparsentan
- sa-mRNA for COVID (near term) & Influenza (medium term)
- aQIVc



Strengthen our Core Platforms

- Flu Cell Culture yield
- Iron evidence & optimisation
- Patient Blood Management
- Ig yield



Long Term, Sustainable Growth



1

Consistent strategy & disciplined execution



2

Targeted R&D with continuous innovation



3

Commitment to sustainability



CSL is committed to a healthier world. **Our vision** is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a values-driven culture

Creating Value



A healthy, more productive society



Sustainable financial growth



Social and economic opportunity



Our Promise to patients

Sustainability Framework

ENVIRONMENTAL

Delivering on our promise to preserve a healthier planet

- Environmental Considerations
- Reduce Carbon Emissions
- Reduce Waste & Emissions in the Supply Chain

SOCIAL

Providing better care for brighter days ahead

- Donor Experience
- Patient & Public Health Leader
- Access to Our Therapies

SUSTAINABLE WORKFORCE

It's the people behind our promise that makes us different

- Employee rights and DEI
- Talent attraction, development and retention
- Supplier diversity

Positioned for Annual Double-Digit Earnings Growth



**Leading
positions in high
growth markets**



**Robust
R&D Portfolio**



**Yield &
capacity
expansion**



**Disciplined
capital allocation
for growth**

The CSL logo consists of the letters 'CSL' in a bold, white, sans-serif font, centered within a solid red square.

Thank You / Questions